BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2014
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
VIMIZIM (elosulfase alfa) by BioMarin Pharmaceutical. Approved for mucopolysaccharidosis iv type a. First approved in 2014.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIMIZIM (elosulfase alfa) is a recombinant hydrolytic lysosomal enzyme approved by the FDA in February 2014 for intravenous injection. It is indicated for the treatment of mucopolysaccharidosis IVb (Morquio B syndrome), a rare lysosomal storage disorder caused by deficiency of the enzyme N-acetylgalactosamine-6-sulfatase. The drug works by replacing the deficient enzyme to reduce accumulation of glycosaminoglycans in lysosomes, slowing disease progression in this severe genetic condition.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Indications (1)
Career Relevance
VIMIZIM creates specialized career opportunities in orphan drug commercialization, including roles for rare disease specialists, genetic disorder MSLs, and field teams with expertise in ultra-rare disease identification and patient registries. Success in this role requires deep knowledge of lysosomal storage disorders, relationships with metabolic genetics specialists, and experience navigating complex orphan drug reimbursement. Currently, zero open positions are linked to this product in available job data.
Worked on VIMIZIM at BioMarin Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.